STORM Therapeutics: $56 Million Raised To Advance RNA-Targeting Cancer Therapy And Phase 2 Sarcoma Trial
By Amit Chowdhry ● Today at 3:04 AM
STORM Therapeutics, a clinical-stage biotechnology company focused on targeting RNA modifications to reprogram cells and develop novel cancer therapies, announced it has raised $56 million in a Series C financing round and dosed the first patient in its Phase 2 sarcoma trial for lead candidate STC-15. The Series C financing was backed by existing investors including M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, UTokyo Innovation Platform Co., Ltd., and Fast Track Initiative.